申请人:Janssen Pharmaceutica NV
公开号:US20190209539A1
公开(公告)日:2019-07-11
Disclosed are compounds, compositions and methods for treating and/or ameliorating diseases, syndromes, disorders, or conditions associated with AR mutant receptors linked to castration-resistant prostate cancer, in a subject, including a mammal and/or human, in need thereof, who has demonstrated resistance to a first or second generation AR antagonist, comprising, consisting of, and/or consisting essentially of, administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula (I)
wherein R
1
, G, R
10
, and R
11
are defined herein.